132 related articles for article (PubMed ID: 37171721)
1. Pharmacokinetics, safety, and antitumor activity of talazoparib monotherapy in Chinese patients with advanced solid tumors.
Luo Y; Cheng Y; Wu C; Ye H; Chen N; Zhang F; Wei H; Xu B
Invest New Drugs; 2023 Jun; 41(3):503-511. PubMed ID: 37171721
[TBL] [Abstract][Full Text] [Related]
2. Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study.
Naito Y; Kuboki Y; Ikeda M; Harano K; Matsubara N; Toyoizumi S; Mori Y; Hori N; Nagasawa T; Kogawa T
Invest New Drugs; 2021 Dec; 39(6):1568-1576. PubMed ID: 34160752
[TBL] [Abstract][Full Text] [Related]
3. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
de Bono JS; Mehra N; Scagliotti GV; Castro E; Dorff T; Stirling A; Stenzl A; Fleming MT; Higano CS; Saad F; Buttigliero C; van Oort IM; Laird AD; Mata M; Chen HC; Healy CG; Czibere A; Fizazi K
Lancet Oncol; 2021 Sep; 22(9):1250-1264. PubMed ID: 34388386
[TBL] [Abstract][Full Text] [Related]
4. Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses.
Mehra N; Fizazi K; de Bono JS; Barthélémy P; Dorff T; Stirling A; Machiels JP; Bimbatti D; Kilari D; Dumez H; Buttigliero C; van Oort IM; Castro E; Chen HC; Di Santo N; DeAnnuntis L; Healy CG; Scagliotti GV
Oncologist; 2022 Oct; 27(10):e783-e795. PubMed ID: 36124924
[TBL] [Abstract][Full Text] [Related]
5. Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline
de Bono J; Ramanathan RK; Mina L; Chugh R; Glaspy J; Rafii S; Kaye S; Sachdev J; Heymach J; Smith DC; Henshaw JW; Herriott A; Patterson M; Curtin NJ; Byers LA; Wainberg ZA
Cancer Discov; 2017 Jun; 7(6):620-629. PubMed ID: 28242752
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of talazoparib in Japanese patients with germline BRCA-mutated locally advanced or metastatic breast cancer: results of the phase 1 dose-expansion study.
Kotani H; Masuda N; Yamashita T; Naito Y; Taira T; Inoue K; Takahashi M; Yonemori K; Toyoizumi S; Mori Y; Nagasawa T; Hori N; Iwata H
Breast Cancer; 2022 Nov; 29(6):1088-1098. PubMed ID: 35907135
[TBL] [Abstract][Full Text] [Related]
7. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
Litton JK; Rugo HS; Ettl J; Hurvitz SA; Gonçalves A; Lee KH; Fehrenbacher L; Yerushalmi R; Mina LA; Martin M; Roché H; Im YH; Quek RGW; Markova D; Tudor IC; Hannah AL; Eiermann W; Blum JL
N Engl J Med; 2018 Aug; 379(8):753-763. PubMed ID: 30110579
[TBL] [Abstract][Full Text] [Related]
8. Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial.
Yap TA; Bardia A; Dvorkin M; Galsky MD; Beck JT; Wise DR; Karyakin O; Rubovszky G; Kislov N; Rohrberg K; Joy AA; Telli ML; Schram AM; Conte U; Chappey C; Stewart R; Stypinski D; Michelon E; Cesari R; Konstantinopoulos PA
JAMA Oncol; 2023 Jan; 9(1):40-50. PubMed ID: 36394849
[TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetics of Talazoparib in Patients With Advanced Cancer.
Yu Y; Durairaj C; Shi H; Wang DD
J Clin Pharmacol; 2020 Feb; 60(2):218-228. PubMed ID: 31489639
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: results of a Phase I study in Chinese patients with advanced solid tumours.
Yuan P; Shentu J; Xu J; Burke W; Hsu K; Learoyd M; Zhu M; Xu B
Cancer Chemother Pharmacol; 2019 May; 83(5):963-974. PubMed ID: 30887180
[TBL] [Abstract][Full Text] [Related]
11. Exposure-Safety Analyses of Talazoparib in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA and ABRAZO Trials.
Elmeliegy M; Yu Y; Litton JK; Czibere A; Wilson GG; Tudor IC; Zheng J; Wang DD
J Clin Pharmacol; 2020 Oct; 60(10):1334-1343. PubMed ID: 32468645
[TBL] [Abstract][Full Text] [Related]
12. Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors.
Dhawan MS; Bartelink IH; Aggarwal RR; Leng J; Zhang JZ; Pawlowska N; Terranova-Barberio M; Grabowsky JA; Gewitz A; Chien AJ; Moasser M; Kelley RK; Maktabi T; Thomas S; Munster PN
Clin Cancer Res; 2017 Nov; 23(21):6400-6410. PubMed ID: 28790114
[No Abstract] [Full Text] [Related]
13. Pharmacokinetics, pharmacodynamics and efficacy of pemigatinib (a selective inhibitor of fibroblast growth factor receptor 1-3) monotherapy in Chinese patients with advanced solid tumors: a phase i clinical trial.
Deng T; Zhang L; Shi Y; Bai G; Pan Y; Shen A; Han X; Yang Z; Chen M; Zhou H; Luo Y; Zheng S; Ba Y
Invest New Drugs; 2023 Dec; 41(6):808-815. PubMed ID: 37889382
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study.
Zhang L; Li S; Zhang Y; Zhan J; Zou BY; Smith R; Martin PD; Jiang Y; Liao H; Guan Z
Clin Ther; 2011 Mar; 33(3):315-27. PubMed ID: 21600385
[TBL] [Abstract][Full Text] [Related]
15. Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours.
Plummer R; Swaisland H; Leunen K; van Herpen CM; Jerusalem G; De Grève J; Lolkema MP; Soetekouw P; Mau-Sørensen M; Nielsen D; Spicer J; Fielding A; So K; Bannister W; Molife LR
Cancer Chemother Pharmacol; 2015 Oct; 76(4):723-9. PubMed ID: 26242220
[TBL] [Abstract][Full Text] [Related]
16. First phase 1 clinical study of olaparib in pediatric patients with refractory solid tumors.
Takagi M; Ogawa C; Iehara T; Aoki-Nogami Y; Ishibashi E; Imai M; Kimura T; Nagata M; Yasuhara M; Masutani M; Yoshimura K; Tomizawa D; Ogawa A; Yonemori K; Morishita A; Miyamoto S; Takita J; Kihara T; Nobori K; Hasebe K; Miya F; Ikeda S; Shioda Y; Matsumoto K; Fujimura J; Mizutani S; Morio T; Hosoi H; Koike R
Cancer; 2022 Aug; 128(15):2949-2957. PubMed ID: 35593736
[TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours.
Yonemori K; Tamura K; Kodaira M; Fujikawa K; Sagawa T; Esaki T; Shirakawa T; Hirai F; Yokoi Y; Kawata T; Hatano B; Takahashi Y
Cancer Chemother Pharmacol; 2016 Sep; 78(3):525-31. PubMed ID: 27422301
[TBL] [Abstract][Full Text] [Related]
18. A Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors.
Yamamoto N; Nokihara H; Yamada Y; Goto Y; Tanioka M; Shibata T; Yamada K; Asahina H; Kawata T; Shi X; Tamura T
Cancer Sci; 2012 Mar; 103(3):504-9. PubMed ID: 22145984
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in
Wang J; Zhang Y; Yuan L; Ren L; Zhang Y; Qi X
Aging (Albany NY); 2020 Nov; 13(1):450-459. PubMed ID: 33257598
[TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability, pharmacokinetics, and antitumor activity of adavosertib in Japanese patients with advanced solid tumors: A phase I, open-label study.
Kondo S; Katsuya Y; Yonemori K; Komuro K; Sugeno M; Kawata T; Ghiorghiu D; Meulendijks D; Yamamoto N
Cancer Treat Res Commun; 2024; 39():100809. PubMed ID: 38593512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]